Literature DB >> 12970243

Transplanted skeletal myoblasts can fully replace the infarcted myocardium when they survive in the host in large numbers.

Keiichi Tambara1, Yutaka Sakakibara, Genichi Sakaguchi, Fanglin Lu, Goditha U Premaratne, Xue Lin, Kazunobu Nishimura, Masashi Komeda.   

Abstract

BACKGROUND: It is not clear how many skeletal myoblasts (SM) can survive and exert beneficial effects in the host myocardial infarction (MI) area. We assessed the hypothesis that a large number of SM can replace the MI area with reverse left ventricular (LV) remodeling. METHODS AND
RESULTS: MI was created by left coronary artery ligation in male Lewis rats. Four weeks after ligation, 45 rats had skeletal myoblast transplantation in the MI area. They were randomized into 3 groups according to the number of SM: group I (n=15), 5 x 10(7); group II (n=15), 5 x 10(6); and group III (n=15), 5 x 10(5) cells. Donor SM were obtained from neonatal Lewis rats and directly used without expansion. Another four weeks later, all rats were sacrificed following hemodynamic assessment. All heart sections were stained with anti-fast skeletal myosin heavy chain (FSMHC) antibody to determine the spacial extent of donor myocytes.
RESULTS: Four weeks after transplantation, LV diastolic dimension was decreased, fractional area change was increased, and MI size was decreased maximally in group I. Histological study showed that donor cells positive for FSMHC occupied the MI area with nearly normal wall thickness in group I, in which estimated volume of donor-derived muscle tissue was 40 mm3. In the other groups, FSMHC-positive cells were found only partly in the MI area.
CONCLUSIONS: A large number of freshly isolated neonatal SM can survive in the host and fully replace the infarcted myocardium with reverse LV remodeling in rats with MI.

Entities:  

Mesh:

Year:  2003        PMID: 12970243     DOI: 10.1161/01.cir.0000087430.17543.b8

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  29 in total

Review 1.  Stem cells and cardiac repair: a critical analysis.

Authors:  Jonathan H Dinsmore; Nabil Dib
Journal:  J Cardiovasc Transl Res       Date:  2008-01-31       Impact factor: 4.132

Review 2.  Stem celltherapy for ischemic heart failure.

Authors:  Doreen Rosenstrauch; Gregor Poglajen; Nina Zidar; Igor D Gregoric
Journal:  Tex Heart Inst J       Date:  2005

3.  Myoangiogenesis after cell patch cardiomyoplasty and omentopexy in a patient with ischemic cardiomyopathy.

Authors:  Syde A Taheri; Hasmat Ashraf; Michael Merhige; Robert S Miletich; Sateesh Satchidanand; Chetan Malik; John Naughton; Qiang Zhao
Journal:  Tex Heart Inst J       Date:  2005

4.  The real estate of myoblast cardiac transplantation: negative remodeling is associated with location.

Authors:  Jonathan D McCue; Cory Swingen; Tanya Feldberg; Gabe Caron; Adam Kolb; Christopher Denucci; Somnath Prabhu; Randy Motilall; Brian Breviu; Doris A Taylor
Journal:  J Heart Lung Transplant       Date:  2008-01       Impact factor: 10.247

Review 5.  Angiomyogenesis for myocardial repair.

Authors:  Husnain Kh Haider; Syed Ali Akbar; Muhammad Ashraf
Journal:  Antioxid Redox Signal       Date:  2009-08       Impact factor: 8.401

Review 6.  Systems approaches to preventing transplanted cell death in cardiac repair.

Authors:  Thomas E Robey; Mark K Saiget; Hans Reinecke; Charles E Murry
Journal:  J Mol Cell Cardiol       Date:  2008-03-19       Impact factor: 5.000

7.  MyoCell, a cell-based, autologous skeletal myoblast therapy for the treatment of cardiovascular diseases.

Authors:  Husnain Kh Haider; Ye Lei; Muhammad Ashraf
Journal:  Curr Opin Mol Ther       Date:  2008-12

8.  Implantation of mouse embryonic stem cell-derived cardiac progenitor cells preserves function of infarcted murine hearts.

Authors:  Nicolas Christoforou; Behzad N Oskouei; Paul Esteso; Christine M Hill; Jeffrey M Zimmet; Weining Bian; Nenad Bursac; Kam W Leong; Joshua M Hare; John D Gearhart
Journal:  PLoS One       Date:  2010-07-12       Impact factor: 3.240

9.  The dietary compound curcumin inhibits p300 histone acetyltransferase activity and prevents heart failure in rats.

Authors:  Tatsuya Morimoto; Yoichi Sunagawa; Teruhisa Kawamura; Tomohide Takaya; Hiromichi Wada; Atsushi Nagasawa; Masashi Komeda; Masatoshi Fujita; Akira Shimatsu; Toru Kita; Koji Hasegawa
Journal:  J Clin Invest       Date:  2008-03       Impact factor: 14.808

Review 10.  Cell-based therapy for heart disease: a clinically oriented perspective.

Authors:  Philippe Menasche
Journal:  Mol Ther       Date:  2009-03-10       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.